Skip to main content
Erschienen in: Reactions Weekly 1/2020

01.02.2020 | Case report

Darunavir

Development of resistance in HIV-1 infection: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Lathouwers E, et al. Pooled resistance analyses of darunavir (DRV) once daily (QD) regimens and formulations across 10 clinical studies of treatment-naive (TN) and treatment-experienced (TE) patients with human immunodeficiency virus (HIV)-1 infection. Open Forum Infectious Diseases 6 (Suppl. 2): S870-S871 abstr. 2509, Oct 2019. Available from: URL: http://doi.org/10.1093/ofid/ofz360.2187 [abstract]CrossRef Lathouwers E, et al. Pooled resistance analyses of darunavir (DRV) once daily (QD) regimens and formulations across 10 clinical studies of treatment-naive (TN) and treatment-experienced (TE) patients with human immunodeficiency virus (HIV)-1 infection. Open Forum Infectious Diseases 6 (Suppl. 2): S870-S871 abstr. 2509, Oct 2019. Available from: URL: http://​doi.​org/​10.​1093/​ofid/​ofz360.​2187 [abstract]CrossRef
Metadaten
Titel
Darunavir
Development of resistance in HIV-1 infection: case report
Publikationsdatum
01.02.2020
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2020
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-020-74936-5

Weitere Artikel der Ausgabe 1/2020

Reactions Weekly 1/2020 Zur Ausgabe

Case report

Infliximab

Case report

Cisplatin

Case report

Meropenem

Case report

Lidocaine

Case report

Apixaban